Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line Setting

NCT04413201 is registered in ClinicalTrials.gov with Michael Hopp as lead sponsor.

NCT NCT04413201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04413201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line Setting
Lead sponsor
Michael Hopp
Phase
Phase 4
Overall status
Active, not recruiting
Start date
September 11, 2020
Completion date
December 31, 2026
Enrollment
34 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous nsclc